Navigation Links
Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
Date:6/11/2009

SAN FRANCISCO, June 11 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada), a clinical-stage biopharmaceutical company, announced today that a $10 million grant from the Ontario Institute for Cancer Research (OICR) has been received by the Centre for Cancer Therapeutics at Ottawa Hospital Research Institute (OHRI). A large portion of this grant will fund research and development in the lab of Dr. John Bell, Jennerex's chief collaborator for the discovery and development of oncolytic viral therapeutics for cancer patients. Funding will support the translation of discoveries into medical products with the potential to prolong the lives of cancer patients. The grant, which provides $10 million (CAD) over four years, will fund the research and development of novel therapeutics including the development of Jennerex's oncolytic viral therapy products. Jennerex products have shown tumor destruction and safety in Phase 1 and 2 clinical trials.

"We are very pleased that Dr. Bell and Jennerex's oncolytic virus technologies have been given this vote of confidence by the Ontario Institute for Cancer Research. This funding will bolster the translation of Dr. Bell's promising research into important cancer therapeutics," stated David H. Kirn, M.D., president and chief executive officer of Jennerex. "We believe that there is significant potential in Ontario for medical innovation and development, and we value our partnerships in Ontario a great deal."

"This collaboration has been a great example of academia and industry working together to translate biological research into cutting edge therapies quickly and effectively," said Dr. John Bell, Senior Scientist at the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa.

Jennerex is conducting Phase 2 clinical trials for several types of cancer in Ontario, Canada. In addition, the company has a strong and co
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...v.24/PRNewswire/--SpartaSystems,Inc.,themakerofTra...yandcompliancesolutions,todayannouncedthatSSLInter...yandtheparentcompanyforgloballyrecognizedbrandssuc...seQualityManagementSystem(EQMS).Thecompanyisnowlev...ualityoperationsthatincludeCorrectiveandPreventive...
(Date:11/24/2009)....24/PRNewswire-Asia/--HuifengBio-Pharmaceutical,Te...operandproducer,ofplantextractsandpharmaceuticalra...foodproductioninXi,an,China,todayreportedthatinits...nues. , RevenuesforthequarterendedSept.30,200...,534,623forthesamequarterin2008.Netincome,amounted...
(Date:11/24/2009)...24/PRNewswire/--MAQUETCardiovascularLLC,aleadingpr...hatithassignedaguaranteedtwo-yearcontractwithNovat...tions,tobethesolesourceproviderofsurgicaldevicesfo...theagreement,whichrunsthroughOctober31,2012,MAQUET...eartdevicesanddisposablesuppliestothemembersofVHAI...
Breaking Medicine Technology:SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices 2MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices 3First Temperature Monitoring Device for Laser Liposuction in St Louis 59886 1Medical Liability Monitor Annual Survey of Medical Malpractice Insurance Rates Shows Medical Liability Insurance Market Remains Soft 59883 1Medical Liability Monitor Annual Survey of Medical Malpractice Insurance Rates Shows Medical Liability Insurance Market Remains Soft 59883 2Drunk Drivers Scarier Than Ghosts and Goblins This Halloween 59880 1Drunk Drivers Scarier Than Ghosts and Goblins This Halloween 59880 2Drunk Drivers Scarier Than Ghosts and Goblins This Halloween 59880 3
(Date:11/25/2009)....25/PRNewswire/--IntroducingPariBeautyProfessional...ncedskincarededicatedtoprovidingprestigeformulasat...tigeskincareandcolorcosmeticbrandtolaunchunderMake...cesinSanFranciscoandToronto,wasfoundedandismanaged...ver35yearsexperienceintheindustry.PariBeautywillha...
(Date:11/25/2009)... Adam DreamHealer’s Global Intention Heals ...nges the physiology of someone at a distance. Over...time unknown to a volunteer who was monitored by a...experts in the USA and Canada. , ... Adam DreamHealer’s Global Intention Heals...
(Date:11/25/2009)... New minimally-invasive procedures that provide p... the risk of sinusitis, or sinus infection, are be...lanta Snoring Institute. Techniques such as ballo...without having to remove any bone or tissue like t...se breakthroughs in treating sinus symptoms were f...
(Date:11/24/2009)...ith a computerized order entry/decision support sy...aging appropriateness at the time of ordering may ...zation, according to an article in the December is...iology , (JACR, www.jacr.org ). , "Imaging exam...ten more costly, diagnostic techniques, and have r...
(Date:11/24/2009)....24/PRNewswire-USNewswire/--OnFriday,November20,ju...ivedafatalblowtotheheadduringatitleboutinPhiladelp...rtstosavehislifewereconducted,hewasdeclaredbrainde...ofitorganprocurementorganization(OPO)servingeaster...tactedbythehospitalaspartofstandardclinicalprocedu...
Breaking Medicine News(10 mins):Health News:Pari Beauty Professional Artistry 2Health News:Intriguing Scientific Results from World's Largest Intention Healing Project: DreamHealer 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 2Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 3Health News:Atlanta Snoring Institute Uses Breakthrough Techniques to Treat Sinusitis and Sinus Pain 4Health News:Computerized order entry/decision support systems: Effective solution to managing imaging utilization 2Health News:Paying Tribute to Boxer Francisco 'Paco' Rodriguez 2
...rug is OK for a certain age is often misunderstood...The labeling on children,s over-the-counter cold m...has found. , Simpler language and clearer graphics...nternal medicine and pediatrics at Vanderbilt Univ...
...sity of Maryland School of Medicine have found tha...is reduces severe illness and death in mice expose... that tempering the response of the body,s immune ...e June 1 edition of The Journal of Immunology , ...
...ging can measure how well patients with the most ...ositive type - respond to standard aromatase inhib...r findings that more invasive needle sampling iden...nd a glucose analogue called FDG, a research team ...
...dy published online in the journal Obesity provi...over eating habits such as determining how much a...foods during early childhood may not lead to sign...uggest that controlling maternal feeding practices...
...ay 26 A short, preoperative team briefing prior t...speaks - improves communication and reduces errors...t Mayo Clinic. , , Mayo researchers believe thi...s were categorized as patient-related issues, equi...
...searcher Alfred Lane, MD, offers sunscreen safety ...iation damage, warns Lane , , STANFORD, Calif., M...mer and kids love sun. However, Dr. Lane cautions,.../www.newscom.com/cgi-bin/prnh/20090526/SF21827 ) ,...
Other Medicine News:Health News:Parents Often Puzzled by Medicine Labels 2Health News:Parents Often Puzzled by Medicine Labels 3Health News:Parents Often Puzzled by Medicine Labels 4Health News:Arthritis drug might prove effective in fighting the flu, study suggests 2Health News:Arthritis drug might prove effective in fighting the flu, study suggests 3Health News:PET scan can non invasively measure early assessment of treatment for common type of breast cancer 2Health News:Strict maternal feeding practices not linked to child weight gain 2Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 2Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 3Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 4Health News:There's No Such Thing as a Good Tan 2Health News:There's No Such Thing as a Good Tan 3
Single Piece PMMA Lens
...Chamber Lenses: The Bausch & Lomb PMMA Posterior C...for primary implantation for the visual correction...here a cataractous lens has been removed by extrac...ded to be placed in the ciliary sulcus or capsular...
Single-Piece PMMA Expand® Series
Multipiece - Sulcus Fixation
Medicine Products: